NEW YORK (TheStreet) -- Athersys (ATHX - Get Report) plummeted more than 55% to a one-year low of $1.09 on Monday after the biotechnology company announced that its experimental stem-cell therapy to treat the inflammatory bowel disease ulcerative colitis did not show any benefits in patients in a mid-stage trial.
Athersys' partner Pfizer (PFE) conducted the trial, in which the therapy did not show a statistically significant decrease in the severity of ulcerative colitis in patients with moderate to severe cases of the disease when compared to a placebo. The therapy also did not significantly reduce rectal bleeding when compared to a placebo.
Must Read: Warren Buffett's 10 Favorite Growth Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts